Prof. Arben Merkoçi, together with Dr. Ruslan Alvarez Diduk and Dr. Marianna Rossetti, are today in #Thessaloniki, Greece, in the Kick off meeting of #2D-BioPad HORIZON project “#Graphene Bio-Platform for point-of-care early detection and monitoring of #Alzheimer’s Disease”.
2D-BioPad project belongs to the Work programme HORIZON-CL4-2022-DIGITAL-EMERGING-02-19, being a #Research and #Innovation Action that during 48 months (October 2023- September 2027) and a funding of €5.957.949 with 11 partners from #EU, coordinated by #CATRIN – #RCPTM, will be focused on novel technologies offering solutions for early diagnostics of Alzheimer’s Disease (#AD).
AD is one of the deadliest #disease that along with cancer and diabetes it is expected to affect roughly 18.8 million people by 2050 in #Europe.
Happy that ICN2, Institut Català de Nanociència i Nanotecnologia (ICN2), will be part of 2D-Bio-Pad consortium and work together with EU partners in this very #challenging project.
2D-BioPAD aims to introduce a fast and cost-effective, non-invasive, reliable, digitally and graphene enabled Point-of-Care (PoC) in vitro #diagnostics (IVD) system for supporting the early diagnosis and progression monitoring of AD directly at primary #healthcare settings. To achieve this, the technological and market gap of #PoC #IVD for AD, 2D-BioPAD leverages the unique properties of 2D materials, such as graphene and its derivatives. Towards that direction, 2D-BioPAD goes beyond the state-of-the- art of its 2D Materials’ pioneer consortium to deliver a graphene-based PoC IVD system that will (i) introduce a versatile surface chemistry that combines #nano and DNA technologies towards improved biocompatibility, stability, as well as high sensitivity and specificity for enhanced (bio-)#sensing; (ii) be able to reliably identify and quantify in real-time and simultaneously up to five AD biomarkers in blood samples effectively supporting healthcare professionals in early diagnosis; (iii) offer an easy to use and understand digital interface with key metrics and insights regarding the measured results; and (iv) employ Artificial Intelligence (#AI) to improve the overall system implementation.
The 2D-BioPAD system and impact will be demonstrated in three clinical centres in Europe (#Finland, #Greece and #Germany) under two clinical pilot studies. In every step, and from the very beginning, 2D-BioPAD will go beyond current norms and involve a wide range of stakeholders, starting from the clinic itself, and led by industrial partners, to identify the essential safety and ethical-by-design principles and guidelines that can accelerate uptake at primary healthcare settings and maximise acceptance and impact to both physical and digital supply chains.
More info at: https://lnkd.in/d6992gtx
#2DBioPad #HorizonEurope #nanobiosensor #PointOfCareDiagnostics #AlzheimerDisease
